Research article

pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea

Soon Kew Park[1], Jung Yoo Lee[1], Chulhun Ludgerus Chang*[2], Min Ki Lee[1], Han Chul Son[2], Cheol Min Kim[3], Hyun Jung Jang[4], Hee Kyung Park[4] and Seok Hoon Jeong[5]

Address: [1]Department of Internal Medicine, College of Medicine, Pusan National University, Korea, [2]Department of Clinical Pathology, College of Medicine, Pusan National University, Korea, [3]Department of Biochemistry, College of Medicine, Pusan National University, Korea, [4]Research Institute, SJ-Hightech Co., Ltd., Korea and [5]Department of Clinical Pathology, Kosin University Medical College, Korea

E-mail: Soon Kew Park - snkpark@hyowon.cc.pusan.ac.kr; Jung Yoo Lee - ljy9039@hitel.net; Chulhun Ludgerus Chang* - cchl@hyowon.cc.pusan.ac.kr; Min Ki Lee - mklee@hyowon.cc.pusan.ac.kr; Han Chul Son - hacson@hyowon.cc.pusan.ac.kr; Cheol Min Kim - kimcm@hyowon.cc.pusan.ac.kr; Hyun Jung Jang - biochiphyun@hotmail.com; Hee Kyung Park - dnachiphk@hotmail.com; Seok Hoon Jeong - kscpjsh@ns.kosinmed.or.kr
*Corresponding author

Abstract

Background: Pyrazinamide (PZA) is among the first-line drugs for the treatment of tuberculosis. In vitro, it kills semidormant mycobacteria only at low pH. The purpose of this study was to compare PZA resistance with pyrazinamidase (PZase) activity and the genotype to better understand the molecular basis of PZA resistance and to expand the profile of pncA mutations worldwide.

Results: Of the 28 tested strains of Mycobacterium tuberculosis, 6 were susceptible to PZA and positive for PZase activity and had no pncA mutations. Twenty-one strains were resistant to PZA and negative for PZase activity and had mutations in the pncA gene, including 15 point mutations, 5 insertions, and 2 deletions. One strain had no mutation in the pncA gene, even though it was resistant to PZA and negative for PZase activity. Three isolates had adenine to guanine point mutations in the -11 upstream region, making this the most common type of pncA mutations in this study, with at least two different RFLP patterns.

Conclusion: These data help in the understanding of the molecular basis of PZA resistance. An adenine to guanine point mutation in the -11 upstream region was the most common type of pncA mutation in our isolates. The results of pncA mutation analyses should be carefully interpreted for epidemiologic purposes.

Background

Pyrazinamide (PZA) is among the first-line drugs used to treat tuberculosis. In vitro, it kills semidormant mycobacteria only at low pH [1]. In vitro susceptibility testing sometimes fails because of the poor growth of mycobacteria at low pH. Therefore, the pyrazinamidase (PZase) test, which was originally used for the differentiation of Mycobacterium tuberculosis from weakly niacin-positive strains of M. bovis, has been used to identify susceptible strains of M. tuberculosis, because PZase converts

the prodrug PZA to pyrazinoic acid, the active form of the drug [2]. The *pncA* gene encodes PZase, and mutations in *pncA* are associated with resistance to PZA or loss of PZase activity [3]. The purpose of this study was to compare PZase activity with the genotype to better understand the molecular basis of PZA resistance and to expand the profile of *pncA* mutations worldwide.

Materials and Methods

Bacterial strains, PZA susceptibility and PZase activity

Twenty-eight clinical isolates of *M. tuberculosis* were included. Twenty-three PZase-negative clinical isolates were provided from Korean Institute of Tuberculosis, and these strains had originally been collected from various sites in this country for the purpose of susceptibility testing. Five PZase-positive isolates were collected randomly among the clinical isolates grown at Pusan National University Hospital (PNUH). The type strain *M. tuberculosis* H37Rv was included as a PZA-susceptible, and thus PZase-positive, control. All isolates were grown in Löwenstein-Jensen medium at 37°C for 3 to 4 weeks. The PZA susceptibility was tested by using Löwenstein-Jensen medium at pH 5.6 with 100 and 500 µg of PZA per mL [4]. The PZase assay was performed by the method described in the Clinical Microbiology Procedure Handbook [2]. Briefly, 6.5 g of Dubos broth base, 0.1 g of PZA, 2.0 g of sodium pyruvate and 15.0 g of agar were dissolved in 1 L of distilled water and heated to dissolve the components. The solution was dispensed in 5-mL amounts into screw-cap tubes and stored at 2 to 8°C until use after solidification of the agar with the tubes in an upright position. A heavy loopful of growth from an actively growing subculture was inoculated. After incubation at 37°C for 4 or 7 days, 1 mL of freshly prepared 1% ferrous ammonium sulfate was added to each tube. A pink band in the agar indicated a positive test.

Genomic DNA preparation, PCR and DNA sequencing

DNA was extracted using an InstaGene matrix kit (Bio-Rad Laboratories Inc., Hercules, CA). A 720-bp segment, including the entire open reading frame, of the *pncA* gene was amplified by using the conditions and the set of primers P1 and P6 [5]. The PCR products were cut from the gel and purified with the QiaAmp PCR purification kit (QIAGEN GmbH, Germany), according to the manufacturer's instructions. The gel-purified PCR products were quantitated, adjusted to a 200-µmol concentration, and used for direct sequencing by the ABI 377 automatic DNA sequencer (Applied Biosystems Inc., Foster, CA) with 4 pM of each of the above-mentioned primers. The RFLP analysis (Figure 1) was performed by an internationally standardized method for the three clinical isolates showing the same *pncA* mutations [6], and the hybridized membrane was detected by the colorimetric method using the Roche digoxigenin detection kit (F.


Figure 1
RFLP analysis patterns of three strains containing promoter mutations. Lane M, molecular markers; lanes 1-3, tested strains containing -11 upstream adenine to guanine substitutions; lane 4, *M. tuberculosis* H37Rv; lane 5, clinical isolate as a control strain.

Hoffmann-La Roche Ltd., Switzerland). The 245-bp mycobacterial IS probe was amplified by PCR with a DIG DNA labeling kit (Roche) using INS-1 and INS-2 primers.

Results and discussion

All five isolates collected from our hospital were PZase-positive and susceptible to PZA with minimal inhibitory concentrations (MIC) of <100 µg/mL, which is consistent with the initial routine tests. These isolates had *pncA* sequences identical to the published sequences of *pncA*

of *M. tuberculosis* H37Rv [3]. Among the 23 isolates collected from the Korean Institute of Tuberculosis, one was PZase-positive and susceptible to PZA (MIC <100 μg/mL). It had no *pncA* mutation in the entire open reading frame, including the upstream region. All of the remaining 22 isolates were negative for PZase activity and resistant to PZA (MIC >500 μg/mL). Among them, 21 organisms (96%) had mutations in the *pncA* gene. Eleven organisms had twelve point mutations, including two point mutations in one organism, which resulted in one silent mutation, one nonsense mutation, and 10 missense mutations. Of those, six mutations have not previously been described. One strain with a silent mutation actually had another missense-type point mutation. Three isolates had upstream mutations at nucleotide -11, the single most common mutation, resulting in an adenine to guanine change. One had a 3-bp insertion, resulting in a slipped-strand mispairing of PncA. Four had 1- or 2-bp insertions, and two had a 2- or 234-bp deletion, all resulting in frameshift mutations in PncA (Table 1). A clustering tendency was apparent in that 40% (6/15) of the point mutations were located in the region between residues 132 and 142 of the PZase sequence. Among the three strains with the promoter region mutations, one isolate showed a clearly different RFLP pattern from the other two.

The PZase test has been used for the differentiation of *M. tuberculosis* from *M. bovis*, *M. avium* complex from niacin-negative *M. bovis*, and *M. marinum* from *M. kansasii* [2]. The test also has been used for the detection of PZA-resistant *M. tuberculosis* strains [7]. However, the test has a shortcoming in that if old colonies are used, false-negative results may be obtained. It seems that in stationary- or death-phase colonies, the enzyme activity is reduced below the limits needed to get a positive reaction. This explains why one of the 23 strains that had resulted in a negative PZase reaction turned out to be PZase positive in this study.

Of the 22 PZase-negative strains, 21 (96%) showed *pncA* mutations in this study. In other reports [5,8,9], *pncA* mutations were found in 72% to 87% of PZA-resistant strains and in 97% of PZase-negative strains. Sreevatsan et al [9] suggested the possibility of another mechanism of PZA resistance because no mutation in *pncA* or its upper promoter was found in 28% of PZA-resistant *M. tuberculosis* strains. In contrast, Hewlett et al [10] demonstrated the low reproducibility of susceptibility to PZA, and Scorpio et al [5] proved false resistance to PZA in susceptible strains. So, if any other resistance mechanism exists, it plays only a minor role in PZA resistance, and more than 95% of PZA-resistant *M. tuberculosis* strains likely harbor *pncA* mutations in this study.

Table 1: *pncA* nucleotide and amino acid changes in PZase-negative *M. tuberculosis* clinical isolates from Korea

Mutation site	Nucleotide changes	Amino acid changes	No. of isolates
-11	A to G[b]	Mutation in promoter	3
23	TCG insertion	Slipped-strand mispairing	1
41	G41A	Missense (Cys14 Tyr)	1
56	234-bp deletion	Frameshift	1
172	T172C[c]	Missense (Phe58 Leu)	1
190	T190G	Missense (Tyr64 Asp)	1
212	A212G[d]	Missense (His71 Arg)	1
227	C227T[e]	Missense (Thr76 Ile)	1
317	CT insertion	Frameshift	1
382	AG insertion	Frameshift	1
393	GT insertion	Frameshift	1
393	T insertion	Frameshift	1
395	G395T	Missense (Gly132 Val)	2
403	A403C[d]	Missense (Thr135 Pro)	1
407	A407G	Missense (Asp136 Gly)	1
421	C421T	Nonsense (Gln141 Termination)	1
425, 180[a]	C425T[f], C180T	Missense (Thr142 Met), Silent (Gly60 Gly)	1
513	GC deletion	Frameshift	1

[a] Two point mutations, including silent one, in a single strain. [b] Previously described mutation [4, 9, 11, 14, 16]. [c] Previously described mutation [16].
[d] Previously described mutations [13]. [e] Previously described mutation [15]. [f] Previously described mutation [5, 14].

Table 2: Type and frequency of mutations described in the *pncA* promoter region and the region between residues 132 and 142 of the PncA[a]

Mutation site	Nucleotide change	Amino acid change		Frequency
-16~-11	AACGTA to GGCAGTT	Mutation in promoter		1
-12	T to G	Mutation in promoter		1
-11	A to C	Mutation in promoter		1
-11	A to G	Mutation in promoter		13
-7	T to C	Mutation in promoter		1
394	G to A	Gly132	Ser	2
395	G to A or T	Gly132	Asp or Val	4
398	T to C	Ile133	Thr	1
401	C to T	Ala134	Val	3
403	A to C	Thr135	Pro	2
406	G to C	Asp136	His	1
407	A to G	Asp136	Gly	1
410	A to C or G	His137	Pro or Arg	4
413	G to A or C	Cys138	Thr or Ser	5
415	G to C or A	Val139	Leu or Met	5
416	T to C or G	Val139	Ala or Gly	6
421	C to T	Gln141	termination	1
422	A to C	Gln141	Pro	3
424	A to C or G	Thr142	Pro or Ala	2
425	C to A or T	Thr142	Lys or Met	8
402~403	CC insertion	Frameshift		1
407~408	C insertion	Frameshift		1
416~417	TG deletion	Frameshift		1
395~411	17-bp deletion	Frameshift		1

[a] The mutations described here were cited from references [4, 5, 9, 11,12,13,14, 16] and the present study

Twenty-two mutations included single nucleotide substitutions, resulting in silent, missense, or nonsense mutations, and deletions and insertions of as many as 234 nucleotides. Of those, six single point mutations in seven strains have not been described in previous studies [3, 4, 5, 9, 11, 12, 13, 14, 15, 16]. These mutations are arrayed along virtually the entire length of the gene [9], even though a clustering tendency was apparent in that 40% (6/15) of the single point mutations were located in the region between residues 132 and 142 of the PZase. The clustering tendency in this region was described previously [5, 12]. In addition, however, we think that attention should be paid to the mutations in the promoter region, especially the -11 upstream region. Although no strains having this type of mutation were described in some studies, the results of other studies, including the present one, demonstrate that it is the most common type of *pncA* mutation [4, 5, 9, 11, 13, 14, 16] (Table 2). Moreover, most of the mutations were substitutions of guanine for adenine. The consensus sequence TATAAT, known as the pribnow box or -10 site, is located approximately 10 bp upstream of the transcription start site of many bacterial genes. So, it seems that mutation of the -11 upstream site blocks binding of RNA polymerase to the promoter site, resulting in inhibition of transcription in the correct place. However, further experiments such as *in vitro* mutagenesis should be performed to demonstrate the relation between the promoter mutation and loss of PZase activity. Theoretically, the same mutations of the *pncA* genes would rarely be present in unrelated isolates because mutations occur randomly along the whole *pncA* gene. Therefore, *pncA* mutations could be a useful tool for epidemiologic investigations. In fact, Cheng et al reported that 21 strains having the same mutations were found to be highly related by molecular typing, suggesting an outbreak from a single source [4]. However, the same mutations within a region with a clustering tendency, such as the -11 upstream region and the region between residues 132 and 142, do not necessarily mean related strains. In the present study, one of the strains with the promoter mutation showed an RFLP pattern different from those of the other two, suggesting different sources of infection. In fact, the three strains were collected during the years 1985, 1990 and 1993, and the two strains of the same guanine to thymine substitution at nt 395 were collected in 1990 and 1997, suggesting that strains with the same mutations came from

different sources. Thus, we think that *pncA* mutations should be applied carefully for epidemiologic analysis.

Conclusion

These data provide a better understanding of the molecular basis of PZA resistance and expand the data on *pncA* mutations worldwide. Furthermore, it was demonstrated that adenine to guanine point mutations in the -11 upstream region are the most common type of *pncA* mutations. Because of the different RFLP patterns in the strains having the same mutations, the results of *pncA* mutations should be carefully interpreted for epidemiologic purposes.

Competing interests

Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this paper? No

Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this paper? No

Do you have any other financial competing interests? No

Are there any non-financial competing interests you would like to declare in relation to this paper? No

References

1. Heifets L, Lindholm-Levy P: **Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations.** *Am Rev Respir Dis* 1992, **145**:1223-5
2. Isenberg HD: **Mycobacteriology: Identification tests for mycobacteria.** *In Clinical Microbiology Procedure Handbook. Edited by Isenberg HD,vol. 1. Washington DC: ASM Press,* 1995, **3**:12-17
3. Scorpio A, Zhang Y: **Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.** *Nat Med* 1996, **2**:662-7
4. Cheng SJ, Thibert L, Sanchez T, Heifets L, Zhang Y: **pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.** *Antimicrob Agents Chemother* 2000, **44**:528-32
5. Scorpio A, Lindholm Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M, Zhang Y: **Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.** *Antimicrob Agents Chemother* 1997, **41**:540-3
6. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, Hermans P, Martin C, McAdam R, Shinnick TM, *et al*: **Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.** *J Clin Microbiol* 1993, **31**:406-9
7. Konno K, Feldmann FM, McDermott W: **Pyrazinamide susceptibility and amidase activity of tubercle bacilli.** *Am Rev Respir Dis* 1967, **95**:461-9
8. Hirano K, Takahashi M, Kazumi Y, Fukasawa Y, Abe C: **Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis.** *Tuber Lung Dis* 1997, **78**:117-22
9. Sreevatsan S, Pan X, Zhang Y, Kreiswirth BN, Musser JM: **Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms.** *Antimicrob Agents Chemother* 1997, **41**:636-40
10. Hewlett D Jr, Horn DL, Alfalla C: **Drug-resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing.** *JAMA* 1995, **273**:916-7
11. Marttila HJ, Marjamaki M, Vyshnevskaya E, Vyshnevskiy BI, Otten TF, Vasilyef AV, Viljanen MK: **pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia.** *Antimicrob Agents Chemother* 1999, **43**:1764-6
12. Lemaitre N, Sougakoff W, Truffot-Pernot C, Jarlier V: **Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA.** *Antimicrob Agents Chemother* 1999, **43**:1761-3
13. Morlock GP, Crawford JT, Butler WR, Brim SE, Sikes D, Mazurek GH, Woodley CL, Cooksey RC: **Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis.** *Antimicrob Agents Chemother* 2000, **44**:2291-5
14. Mestdagh M, Fonteyne PA, Realini L, Rossau R, Jannes G, Mijs W, De Smet KA, Portaels F, Van den Eeckhout E: **Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.** *Antimicrob Agents Chemother* 1999, **43**:2317-9
15. Brown TJ, Tansel O, French GL: **Simultaneous identification and typing of multi-drug-resistant Mycobacterium tuberculosis isolates by analysis of pncA and rpoB.** *J Med Microbiol* 2000, **49**:651-6
16. Escalante P, Ramaswamy S, Sanabria H, Soini H, Pan X, Valiente-Castillo O, Musser JM: **Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru.** *Tuber Lung Dis* 1998, **79**:111-8

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/content/backmatter/1471-2334-1-4-b1.pdf